Evidence map›Paper›PMID 42520158›Full record

ArticleBriefings in bioinformatics2026

Multi-tissue integrated Mendelian randomization method identifies disease risk genes.

Yu Cheng, Shuhan Liu, Xinjia Ruan, Zhonghua Li, Liyun Jiang, Tiantian Liu, Fangrong Yan

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu Cheng *Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.
Shuhan Liu *Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.
Xinjia Ruan *Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.ORCID 0000-0003-2309-2641
Zhonghua LiResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.
Liyun JiangResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.
Tiantian LiuResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.ORCID 0009-0009-4207-8651
Fangrong YanResearch Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, No. 639 Longmian Ave, Jiangning District, Nanjing 211100, Jiangsu, China.ORCID 0009-0004-8673-2321

Funding

2024 National Key Research on Multi-Target Natural Drugs SKLNMZZ2024JS32Fundamental Research Funds for the Central Universities of China Pharmaceutical University 2632023FY04Fundamental Research Funds for the Central Universities of China Pharmaceutical University 2632023FY05Key Laboratory of Scientific and Engineering Computing (Ministry of Education)National Natural Science Foundation of China 82273735National Natural Science Foundation of China 82304252National Natural Science Foundation of China 82473737National Science Foundation for Young Scientists of China 82404380Shanghai Frontiers Science Center of Modern Analysis
6 · The paper itself

Abstract

Mendelian randomization (MR) leverages genetic variants as instrumental variables to infer causal relationships between molecular traits and diseases, however, identifying the specific causal genes underlying disease risk remains challenging. Here, we present MULTI (Multi-tissue Unified Likelihood-based Transcriptomic Integration), a Bayesian MR framework that integrates genetic information across tissues to improve the accuracy of causal inference. MULTI yields reliable estimates even when the number of instruments in a single tissue is limited, and further increases statistical power by adaptively integrating information from similar tissues without inflating type I error rates. Extensive simulations confirm its robustness under diverse genetic architectures, and applications to real datasets demonstrate its capacity to reveal tissue-specific causal mechanisms and coordinated cross-tissue regulation. MULTI offers a practical and extensible framework for elucidating the molecular architecture of complex human diseases.

Indexed as

Genetic Predisposition to DiseaseMendelian Randomization AnalysisBayes TheoremHumansOrgan SpecificityPolymorphism, Single NucleotideQuantitative Trait Locicausal gene identificationcis-eQTLcross-tissue integrationdisease risk genemulti-tissue Mendelian randomization

Identifiers

PMID42520158
PMCPMC13411301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.